Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy

Tran, Anna; Mandall, Paula; Swindell, Ric; Hoskin, Peter; Bottomley, David; Logue, John P; Wylie, James

doi:10.1016/j.radonc.2013.05.030

Cited by 14 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low-dose-rate brachytherapy is an effective, low-morbidity treatment for low to intermediate risk prostate cancer [1, 2, 3, 4, 5]. Although considerable effort has been made to predict 5-year biochemical relapse and disease free survival [6, 7], immediate post treatment monitoring has been debated [8, 9, 10].…”

Section: Purposementioning

confidence: 99%

Parameters predicting for prostate specific antigen response rates at one year post low-dose-rate intraoperative prostate brachytherapy

Martell¹,

Meyer²,

Sia³

et al. 2017

jcb

View full text Add to dashboard Cite

PurposeTo develop a model for prostate specific antigen (PSA) values at one year among patients treated with intraoperatively planned 125I prostate brachytherapy (IOPB).Material and methodsFour hundred and deven patients treated with IOPB for prostate adenocarcinoma were divided into four groups: those with PSA values ≥ 3 ng/ml; < 3 and ≥ 2; < 2 and ≥ 1 or PSA < 1 between 10.5 and 14.5 months post implantation (1yPSA). Ordinal regression analysis was then performed between patient, tumor, and treatment characteristics. 1yPSA values were also compared with toxicity outcomes.ResultsMedian 1yPSA was 0.77 (0.04-17.36). Thirty-two patients (8%) had a PSA ≥ 3; 35 (9%) had PSA < 3, ≥ 2; 87 (21%) had PSA < 2, ≥ 1, and most patients 254 (62%) had PSA < 1. PSA response was independent of gland volume, Gleason score, clinical stage, seed activity, V90, V200, D90, or number of needles and seeds used. Older patients had significantly lower 1yPSA; median ages 65.1 (46.5-81.0), 62.1 (50.4-79.5), 60.5 (47.1-80.3), and 58.1 (45.1-74.2) years for each of the 1yPSA groups respectively (p < 0.001). Also, both implant V150 (p < 0.001) and initial PSA values (p = 0.04) were predictive of 1yPSA values. There was no correlation between 1yPSA values and toxicity encountered.ConclusionsPSA response at 1 year post IOPB appears to be dependent on patient age, initial PSA, and implant V150. Our results provide reassurance that parameters other than biochemical failure influence 1yPSA values.

show abstract

Section: Purposementioning

confidence: 99%

Parameters predicting for prostate specific antigen response rates at one year post low-dose-rate intraoperative prostate brachytherapy

Martell¹,

Meyer²,

Sia³

et al. 2017

jcb

View full text Add to dashboard Cite

show abstract

“…Although this is not presently advocated as a standard approach for GS7 prostate cancer, 2 single-institution studies have demonstrated favorable PSA control. 20,21 We have used this approach selectively for patients without other high-risk features (PSA > 10 ng/mL, T stage T2b or higher); the 5-year biochemical control rate is encouraging (94%) and compares favorably with the other radiation approaches in the present study population. Further investigation with long-term follow-up is warranted to determine which subsets of GS7 patients may be safely treated with this approach.…”

Section: Discussionmentioning

confidence: 82%

What Is the Optimal Management of Gleason Score 7 Prostate Cancer at Biopsy? A Comparison of Disease Control for Prostatectomy Versus Radiotherapy

Watkins

Dufan

et al. 2015

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

“…The median dose per fraction was 4 Gy [3.5 - 4.5] with a median number of fractions of 9 [7-10] (Table 1). The median total delivered dose was 38.5 Gy [34–43] corresponding to a EQD2αβ10 of 46 Gy [41–54] and EQDαβ3 of 57.5 Gy [47–68].…”

Section: Resultsmentioning

confidence: 99%

“…Low and pulsed-dose rate (PDR) brachytherapy represented until recent years the reference technique [15,16]. However, the evolution of brachytherapy techniques, after-loading machines, treatment planning software and more stringent rules of radiation safety have positioned high-dose rate brachytherapy as the reference technique for numerous indication such cervical and prostate tumors [5-7,15,17]. But clinical data of HDR brachytherapy for penis cancer remains rare.…”

Section: Discussionmentioning

confidence: 99%

“…For radioprotection and dose distribution optimization considerations as well as therapeutic comfort of the patient, high-dose rate brachytherapy (HDB) has become a standard treatment in many cancers (cervical [5], breast [6] and prostate [7]). The aim of our study was to evaluate the clinical outcome of HDB for penile cancers classified T1a, T1b or T2 < 4 cm according to the TNM 2009 [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High-dose rate brachytherapy in localized penile cancer: short-term clinical outcome analysis

et al. 2014

View full text Add to dashboard Cite

PurposeTo assess clinical outcomes of high-dose rate interstitial brachytherapy (HIB) in localized penile carcinoma.Material and methodsFrom 03/2006 to 08/2013, patients with biopsy-proven T1-T2 (<4 cm) non-metastatic localized penile squamous cell carcinoma underwent HIB. Under general anaesthesia, after Foley catheter placement, needles were placed in the target volume using a dedicated template. Planification was carried out with a post-implant CT-scan to deliver a total dose of 36 Gy in 9 fractions over 5 days (in adjuvant setting) or 39 Gy in 9 fractions over 5 days (as monotherapy). Dose-volume adaptation was manually achieved using graphical optimization. Dosimetric data and clinical outcomes were retrospectively analyzed. Toxicities were graded using the CTC v4.0.ResultsWith a median follow-up of 27 months [5.1-83], 12 patients including 8 T1a, 3 T1b and 1 T2 N0 underwent HIB (sole therapy: 11 pts; adjuvant: 1 pt). The actuarial 5-year relapse-free, cause-specific and overall survival rates were 83%, 100% and 78% respectively. Comparing pre and post treatment evaluation, no IPSS or IIEF-5 changes were reported. Dermatitis was reported systematically 1 month after HIB including 6 G1, 5 G2 and 1 G3. Only 1 experienced long-term G3 successfully treated with hyperbaric oxygen therapy. One urethral meatus stenosis G3 required meatotomy.ConclusionIn selected patients with T1-T2 localized penile cancer, HIB may be considered as an optional conservative therapy. Longer follow-up is needed to confirm these encouraging preliminary results.

show abstract

Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy

Cited by 14 publications

References 50 publications

Parameters predicting for prostate specific antigen response rates at one year post low-dose-rate intraoperative prostate brachytherapy

Parameters predicting for prostate specific antigen response rates at one year post low-dose-rate intraoperative prostate brachytherapy

What Is the Optimal Management of Gleason Score 7 Prostate Cancer at Biopsy? A Comparison of Disease Control for Prostatectomy Versus Radiotherapy

High-dose rate brachytherapy in localized penile cancer: short-term clinical outcome analysis

Contact Info

Product

Resources

About